DEX‐Induced SREBF1 Promotes BMSCs Differentiation into Adipocytes to Attract and Protect Residual T‐Cell Acute Lymphoblastic Leukemia Cells After Chemotherapy (Adv. Sci. 19/2023).

DEX-Induced SREBF1 Promotes BMSCs Differentiation into Adipocytes to Attract and Protect Residual T-Cell Acute Lymphoblastic Leukemia Cells After Chemotherapy (Adv. Sci. 19/2023) Last, an SREBF1 inhibitor demonstrates superior improvement on therapeutic effect of dexamethason by reducing adipogenesis and provides a feasible strategy to solve the dilemma of recurrence. B T-Cell Acute Lym-phoblastic Leukemia b In article number 2205854, Jingjing Ye, Min Ji, Chunyan Ji, and co-workers observed aberrant adipogenesis in the bone marrow of chemotherapy-treated T-cell acute lymphoblastic leukemia (T-ALL) patients, and the differentiated-adipocytes attract and support residual T-ALL cells. [Extracted from the article]